Budesonide/formoterol maintenance and reliever therapy – effective treatment at a lower cost Source: Annual Congress 2008 - Rationale of self-education in asthma therapy Year: 2008
Budesonide/formoterol maintenance and reliever therapy use in elderly asthma patients Source: Annual Congress 2010 - Combination therapy in asthma and COPD Year: 2010
Formoterol turbuhaler is effective and safe compared with salbutamol by pMDI and spacer as reliever therapy in patients with acute severe asthma Source: Eur Respir J 2002; 20: Suppl. 38, 52s Year: 2002
Budesonide/formoterol maintenance and reliever therapy compared to conventional best practice in the treatment of persistent asthma Source: Eur Respir J 2007; 30: Suppl. 51, 616s Year: 2007
Episodic high reliever use with budesonide/formoterol maintenance and reliever therapy confers added protection against asthma exacerbations Source: Annual Congress 2007 - Recent advances in our understanding of the treatment of asthma Year: 2007
Budesonide/formoterol maintenance and reliever therapy in adolescent patients with asthma Source: Eur Respir J, 51 (1) 1701688; 10.1183/13993003.01688-2017 Year: 2018
Efficacy of long-term formoterol therapy vs as-needed salbutamol use in patients with moderate asthma Source: Eur Respir J 2001; 18: Suppl. 33, 426s Year: 2001
Switching asthma patients using high-dose inhaled steroids to budesonide/formoterol maintenance and reliever therapy Source: Annual Congress 2010 - Management of airway disease Year: 2010
Safety of formoterol reliever therapy compared with terbutaline in asthmatic children taking anti-inflammatory therapy Source: Eur Respir J 2002; 20: Suppl. 38, 431s Year: 2002
Formoterol turbuhaler compared with salbutamol as reliever medication in asthma: an exploratory analysis of the RELIEF study in patients using formoterol as maintenance therapy Source: Eur Respir J 2002; 20: Suppl. 38, 44s Year: 2002
Formoterol turbuhaler as a rescue therapy was as effective and safe as salbutamol by pMDI and spacer in patients with acute severe asthma Source: Eur Respir J 2002; 20: Suppl. 38, 52s Year: 2002
Budesonide–formoterol reliever therapy in intermittent versus mild persistent asthma Source: Eur Respir J, 57 (2) 2003064; 10.1183/13993003.03064-2020 Year: 2021
Tiotropium add-on therapy is safe and reduces seasonal worsening in paediatric asthma patients Source: Eur Respir J, 53 (6) 1801824; 10.1183/13993003.01824-2018 Year: 2019
Budesonide/formoterol maintenance and reliever therapy for asthma in general practice: is it cost-effective? Source: Annual Congress 2008 - Diagnosing, monitoring and treating respiratory diseases in primary care Year: 2008
Budesonide/formoterol single inhaler therapy reduces overreliance on rapid-acting reliever medication Source: Eur Respir J 2004; 24: Suppl. 48, 344s Year: 2004
Short-acting bronchodilator and oral steroid use in asthma patients prescribed either concurrent beclometasone and salmeterol or combined salmeterol/fluticasone Source: Eur Respir J 2004; 24: Suppl. 48, 309s Year: 2004
Budesonide/formoterol maintenance and reliever therapy versus fluticasone/salmeterol fixed-dose treatment in patients with COPD Source: Virtual Congress 2020 – Advances in pharmacological treatment of COPD Year: 2020
As-needed formoterol has an improved safety profile compared with as-needed terbutaline in mild intermittent asthma Source: Eur Respir J 2003; 22: Suppl. 45, 235s Year: 2003
Formoterol Turbuhaler as reliever medication in patients with acute asthma Source: Eur Respir J 2006; 27: 735-741 Year: 2006
NVA237, a once-daily inhaled anticholinergic, provides 24-hour bronchodilator efficacy in patients with moderate-to-severe COPD Source: Eur Respir J 2006; 28: Suppl. 50, 527s Year: 2006